There is evidence that increasing carbohydrate (CHO) availability during exercise by raising pre-exercise muscle glycogen levels attenuates the activation of AMP-activated protein kinase (AMPK) α2 during exercise in humans. Similarly, increasing glucose levels decreases AMPK α2 activity in rat skeletal muscle in vitro. We examined the effect of CHO ingestion on skeletal muscle AMPK signaling during exercise in nine active male subjects who completed two 120 min bouts of cycling exercise at 64±1% VO 2 peak. In a randomized, counter-balanced order, subject's ingested either an 8% CHO solution or a placebo solution during exercise. Compared with the placebo trial, CHO ingestion significantly (P<0.05) increased plasma glucose levels and tracerdetermined glucose disappearance. Exercise-induced increases in muscle calculated free AMP (17.7 vs. 11.8-fold), muscle lactate (3.3 vs. 1.8-fold), and plasma epinephrine were reduced by CHO ingestion. However, the exercise-induced increases in skeletal muscle AMPK α2 activity, AMPK α2 Thr 172 phosphorylation and acetyl-CoA Ser 222 phosphorylation were essentially identical in the two trials. These findings indicate that AMPK activation in skeletal muscle during exercise in humans is not sensitive to changes in plasma glucose levels in the normal range. Furthermore, the rise in plasma epinephrine levels in response to exercise was greatly suppressed by CHO ingestion without altering AMPK signaling, raising the possibility that epinephrine does not directly control AMPK activity during muscle contraction under these conditions in vivo.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a αβγ heterotrimer that has been implicated as an important regulator of energy metabolism (19, 41) . The α subunit of AMPK contains the catalytic domain that is the mammalian homolog of the yeast metabolic stress sensing kinase snf1p (19). Both AMPK α1 and α2 are expressed in skeletal muscle and are activated by phosphorylation at Thr 172 by the AMPK kinase (AMPKK) LKB1 (13, 32, 33, 44) . Once phosphorylated, AMPK can be further activated allosterically by increases in the free AMP:ATP ratio (10, 32). In contracting skeletal muscle of animals and humans, the AMPK α2 isoform is predominately activated (4, 26, 37, 42, 43) . The AMPK β subunit acts as a targeting subunit anchoring both the α and γ subunits (16).
The β subunit also contains a glycogen binding domain that can target the AMPK to glycogen (29).
Initially it was thought that muscle glycogen levels controlled AMPK activity because low muscle glycogen content in rodents and humans was associated with increased AMPK activation (24, 31, 39, 42) . However, although starting exercise with very low muscle glycogen levels appears to result in greater activation of muscle AMPK during exercise (31, 39, 42) , there is no affect of muscle glycogen on AMPK activation during exercise when exercise is started with normal or high muscle glycogen levels after short-term exercise training (24) . Whilst it is possible that muscle glycogen levels may partially regulate AMPK during an acute bout of exercise, it has been shown that when purified AMPK is bound to glycogen there is no effect on enzyme activity (28), and thus other factors appear to be involved.
Aside from manipulating muscle glycogen levels, another way to alter carbohydrate (CHO) availability during exercise is to ingest CHO, which raises plasma glucose levels.
In yeast, glucose deprivation results in the rapid activation of snf1p (40) and similarly in cultured mammalian cells glucose deprivation enhances AMPK activation (7, 34). In contrast, high glucose suppresses AMPK activation as seen with the progressive decreases in basal AMPK activity in rat muscle in vitro with increasing glucose levels from 0 mmol.l -1 to 3 mmol.l -1 to 6 mmol.l -1 to 25 mmol.l -1 (17). Based on these findings, it could be speculated that increasing plasma glucose levels by CHO supplementation may attenuate the increases in skeletal muscle AMPK activity during exercise. In humans, CHO ingestion before and during exercise does not alter the exercise-induced increases in AMPK α Thr 172 or ACC-β Ser 222 phosphorylation during 2 hours of exercise in well-trained individuals (8). However, in that study pre-exercise CHO ingestion was associated with a significant elevation in blood glucose and insulin levels before exercise commenced (8). Furthermore, the exercise-induced increase in AMPK α Thr 172 phosphorylation appeared to be less during exercise with CHO supplementation, although this was not statistically significant (8) . No study has examined whether altering glucose levels during exercise effects AMPK signaling in humans.
Carbohydrate ingestion during exercise significantly increases skeletal muscle glucose uptake when compared with ingesting a placebo solution that contains no CHO (1, 22) .
Furthermore, CHO ingestion during cycling exercise has no affect on muscle glycogen use during exercise (6, 12, 23). As discussed above, given that AMPK activation during Page 4 of 37 exercise may potentially be regulated by muscle glycogen levels (9, 42), CHO supplementation represents a model in which glucose uptake can be significantly increased without altering muscle glycogen levels. CHO ingestion also raises plasma insulin levels during exercise (22) but this is unlikely to affect muscle AMPK activity since insulin has no effect on rat skeletal muscle AMPK activity in vitro (2, 14) .
Similarly, a hyperinsulinemic clamp has no effect on basal skeletal muscle AMPK activity in humans (15).
Aside from glucose, it has also been postulated that skeletal muscle AMPK α2 is regulated by epinephrine since in the soleus muscle of male mice, phenylephrine, an α-adrenergic agonist, increases AMPK α2 activity (25) . Since CHO ingestion attenuates the increase in plasma epinephrine during prolonged exercise (22) it is possible that there may be less activation of AMPK during exercise due to this mechanism.
The effect of CHO ingestion during prolonged cycling exercise on the skeletal muscle energy imbalance is small, with most studies showing either no affect, or a small significant attenuation of the increase in muscle energy imbalance (23, 35) . Since skeletal muscle free AMP (AMP free ) content is the major regulator of AMPK during exercise, if CHO ingestion attenuates the increase in AMP free , then it may also reduce the activation of skeletal muscle AMPK during exercise. Therefore, the aim of this study was to determine whether CHO ingestion during exercise attenuates the increase in skeletal muscle AMPK activity during exercise in humans. We hypothesized that CHO ingestion would reduce the increase in skeletal muscle AMPK activity during exercise (based on higher plasma glucose concentration, lower plasma epinephrine and perhaps lower muscle AMP free ).
METHODS

Participants:
Nine healthy, active, but not specifically exercise-trained, non smoker males provided informed written consent to participate in this study, which was approved by the Human
Research Ethics Committee of The University of Melbourne and conducted in accordance with the Declaration of Helsinki. Participant characteristics were: 21 ± 1 yr, 72.6 ± 4.0 kg, 1.80 ± 0.03 m, VO 2 peak of 3.51 ± 0.25 l.min -1 which equated to 48.5 ± 2.6 ml.kg -1 min -1 .
Experimental procedures:
Participants were required to attend the laboratory on four separate occasions. The first visit involved a peak pulmonary oxygen consumption test during cycling (VO 2 peak), followed by a familiarization session. Subjects then returned to the laboratory for two experimental trials, which involved cycling for 120 min at a workload requiring ~65% VO 2 peak. Over the 24 hr period prior to the experimental trials all participants were instructed to refrain from drinking alcohol and caffeine, and not to perform any formal exercise. Between trials, participants were asked to maintain their regular exercise patterns. To ensure food intake was similar between each experimental trial, the participants were given a food diary to record all food consumed over the 24 hr prior to the first experimental trial, and asked to match as closely as possible this dietary intake over the 24 hr prior to the second experimental trial. In the experimental trials blood was sampled every 15 min during exercise for the measurement of plasma glucose, plasma lactate, as well as glucose kinetics. For plasma catecholamines and insulin blood was collected every 30 minutes. All blood samples were centrifuged at 3,000 x g for 20 min, with plasma stored at -80°C prior to analysis.
Expired air was sampled into Douglas bags for ~15 min at rest, and for three min each 15 min of exercise. Heart rate was monitored throughout exercise using a heart rate monitor (Polar Favor, Oulu, Finland).
Muscle was obtained from the vastus lateralis muscle under local anesthesia using the percutaneous needle biopsy technique, with suction. Prior to commencing exercise three separate incisions were made approximately 1 cm apart and muscle was sampled (in a distal to proximal order) at rest, and immediately following 60 and 120 min of exercise.
One leg was used for each of the experimental trials (chosen at random). Following the 60 min muscle sample, a standard 60 sec period was allowed for completion of the biopsy and taping of the area prior to recommencing exercise. Samples were frozen in liquid nitrogen (LN 2 ) within 6 ± 0 seconds of inserting the needle at rest and within 9 ± 1 seconds of the subject stopping exercise (60 min and 120 min samples). Muscle samples were subsequently stored in LN 2 for later analysis of AMPK α1 and α2 activity, AMPK α2 Thr 172 phosphorylation, ACC-β Ser 222 phosphorylation, and muscle metabolites.
Analytical techniques:
Blood analysis: Plasma glucose and lactate were determined using an automated glucose oxidase and L-lactate oxidase method, respectively (EML 105, Radiometer Pacific, Melbourne, Australia), plasma epinephrine and norepinephrine by an enzyme immunoassay kit (Labor Diagnostika Nord, Nordhorn,Germany) and plasma insulin using a specific human insulin radioimmunoassay kit (Linco Research Inc, St. Charles, MO).
Glucose kinetics were estimated, as previously described (4), using a modified one-pool, non-steady-state model (36) which has been validated (30). Rates of plasma glucose appearance (Glucose Ra) and glucose disappearance (Glucose Rd) were determined from the changes in % enrichment of [6,6-2 H]glucose and plasma glucose concentration.
Glucose clearance rate (Glucose CR) was calculated by dividing the glucose Rd by the plasma glucose concentration. During exercise at ~60% of VO 2 max, 90-95% of tracerdetermined glucose Rd is oxidized (5, 18).
Muscle analysis: A portion (~20 mg) of each muscle sample was freeze-dried then analyzed for muscle glycogen, ATP, creatine phosphate, creatine and lactate as previously described (4) . The estimated free concentrations of ADP and AMP were based on the near equilibrium nature of the creatine phosphokinase and adenylate kinase reactions, respectively. Free ADP (ADP free ) was estimated from the measured ATP, Cr 
Statistical analysis:
The two experimental trials were compared using two factor (treatment x time) repeated measures analysis of variance (ANOVA) utilizing the statistical package SPSS. If the ANOVA was significant (P<0.05), specific differences were located using the Fisher's Least Significant Difference (LSD) test.
RESULTS
Pulmonary gas measures and substrate oxidation
VO 2 averaged 65 ± 1% of VO 2 peak during the placebo trial and 64 ± 2% of VO 2 peak during the CHO trial. CHO supplementation significantly increased RER and CHO oxidation during exercise compared with placebo (P<0.05; Table 1 ). Ventilation and fat oxidation increased similarly during exercise in the two trials although fat oxidation tended to be reduced during exercise with CHO supplementation (P=0.09).
Plasma glucose, lactate, and insulin
Plasma glucose, lactate and insulin concentrations were not different in the two trials before exercise. Plasma glucose concentration was significantly higher in CHO than placebo throughout exercise ( Figure 1A ). Plasma lactate increased to a similar extent in the two trials during exercise but were significantly lower at 120 min of exercise in CHO than placebo ( Figure 1B ). Plasma insulin was significantly higher throughout exercise in the CHO trial ( Figure 1C ).
Glucose kinetics
Glucose Ra (Figure 2A ), glucose Rd ( Figure 2B ), and glucose CR ( Figure 2C ) were all similar at rest in the two trials, and all significantly increased during exercise in both trials. CHO ingestion significantly increased glucose Ra and glucose Rd above that of placebo throughout the exercise period. Glucose CR was significantly higher in CHO than placebo during the last hour of exercise.
Plasma catecholamines
Plasma epinephrine increased during exercise in both trials but plasma epinephrine was significantly lower at the end of exercise in CHO (P<0.01; Figure 3A ). Plasma norepinephrine increased significantly over time in both trials (P<0.001) with no differences observed between the trials (P=0.65; Figure 3 ).
Muscle Metabolites
There was no difference between the two trials in any measured muscle metabolite before exercise ( (Table 2) . Muscle ATP levels were unchanged by exercise in both trials (Table 2 ). In line with the plasma lactate results, muscle lactate content increased during exercise in both trials and was significantly lower at 120 min of exercise in CHO when compared with placebo (Table 2) . Muscle ADP free increased during exercise in both trials, and tended to be lower during the CHO trial, however this was not statistically significant (P=0.06). AMP free and AMP free :ATP ratio increased during exercise in both trials with a significant main effect indicating that both AMP free and AMP free :ATP ratio were lower in
AMPK signaling
AMPK α1 activity ( Figure 5A ) and AMPK α2 activity ( Figure 5B ) increased during exercise performed with or without CHO supplementation with no differences observed between the trials (P=0.6 and P=0.8 for AMPK α1 and α2 activity, respectively). In line with the response to exercise of AMPK α1 and α2 activity, AMPK α2 Thr 172 phosphorylation ( Figure 6A ) and ACC-β Ser 222 phosphorylation ( Figure 6B ) both increased during exercise in both trials with no differences observed between the trials.
DISCUSSION
The major finding of this study was that CHO ingestion during exercise in humans did not alter skeletal muscle AMPK signaling (i.e. AMPK α1 and α2 activity, AMPK α2 In mouse SOL muscle, the α-adrenergic agonist phenylephrine increases AMPK α2 activity ex vivo (25) , suggesting a possible regulatory role for plasma epinephrine in the regulation of AMPK α2 activity. In the present study, the increases in plasma epinephrine levels became more pronounced (~6-fold) over time during exercise with a placebo compared to CHO supplementation ( Figure 3 ). Despite this, no differences were observed in AMPK α2 activity or AMPK α2 Thr 172 phosphorylation during exercise, suggesting that in human skeletal muscle epinephrine is not a regulator of AMPK α2 during exercise. Similarly, we also recently found plasma epinephrine levels did not correlate with AMPK activation during exercise in humans performed under hypoxic conditions compared with during normoxic conditions at the same relative intensity (38).
However, it is possible that only a small increase in plasma epinephrine is required during exercise to exert a regulatory effect on AMPK and thus further research is required to examine the role, if any, of epinephrine in the regulation of AMPK activity during exercise.
In contracting skeletal muscle the AMP free :ATP ratio is considered to be the major regulator of AMPK activity (11, 32), as the activity of the upstream kinase (LKB1) is not changed (32). Indeed, a number of studies have observed parallel changes in skeletal muscle AMP free and AMPK α2 activity during exercise (3, 4, 38) . However, there appeared to be some uncoupling between skeletal muscle calculated AMP free and AMPK activation in the present study. In agreement with this, we have also found during 30 min of exercise at 65% VO 2 peak that there was a progressive increase in AMPK α2 activity but muscle AMP free did not change after the first 5 min of exercise (37). In addition, we recently found no increase in AMPK activity during prolonged exercise at ~60% VO 2 peak after short-term exercise training despite 4-8-fold increases in AMP free during exercise (24) . It should be noted however that although the increase in skeletal muscle AMP free during exercise was significantly attenuated with CHO ingestion (Table 2) ratio is a better indicator of cellular stress (27), and indeed the decreases in PCr:(PCr + Cr) during exercise with placebo and CHO supplementation appeared to couple the increases in AMPK signaling. However, we have also observed a dissociation between changes in PCr:(PCr + Cr) and AMPK signaling during exercise performed after 10 days of exercise training since substantial changes in PCr:(PCr + Cr) were observed during exercise after training but no increases in AMPK activity were observed (24).
In conclusion, CHO supplementation during exercise has no effect on the activation of skeletal muscle AMPK during prolonged exercise in humans. This was despite the fact that CHO ingestion partially reduced the exercise-induced increases in skeletal muscle free AMP. It appears that the modest increase in plasma glucose concentration when CHO is ingested during exercise is insufficient to alter AMPK signaling during exercise.
Further, our results in conjunction with previous findings from our laboratory raise the possibility that plasma epinephrine concentration does not regulate skeletal muscle AMPK α2 activity during exercise in humans, since the reduction in plasma epinephrine levels during CHO ingestion did not alter skeletal muscle AMPK activation/signaling. 
Figure 4
Muscle glycogen at rest (0 min), after 60 minutes, and at the completion of exercise (120 minutes) at 65 ± 1% VO 2 peak conducted with (CHO) or without (Placebo) carbohydrate supplementation. Data are mean ± SEM (n = 9, except n = 8 for placebo at 30 minutes and n = 7 for placebo at 120 minutes). ‡ Main effect for time, P<0.05.
Figure 5
Muscle AMPK α1 activity (A) and AMPK α2 activity (B) at rest (0 min), after 60 minutes, and after 120 minutes of exercise at 65 ± 1% of VO 2 peak. Exercise was performed with (CHO) or without (Placebo) carbohydrate supplementation. Data are mean ± SEM, n = 8. ‡ Main effect for time, P<0.001
Figure 6
Representative blot and mean data of muscle AMPK α2 
